drugset

drugset / Trial / NCT03363334

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

NCT03363334 ↗

Expanded access No longer available Rigel Pharmaceuticals

Summary

C-935788-055 is an open-label, multi-center, expanded access (EAP) study.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fostamatinib	Small molecule	100 mg	Oral
Subject	Fostamatinib	Small molecule	150 mg	Oral

Indications